Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

– Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries.

“Caryn’s substantial industry knowledge and extensive leadership experience developing and implementing HR strategies, talent acquisition, and diversity and inclusion will be critical in guiding Scholar Rock’s accelerated growth plans,” said Nagesh Mahanthappa, Ph.D. Interim CEO of Scholar Rock. “We are honored to have Caryn join the team to grow our company and expand our capabilities during this important juncture as we advance towards late-stage development and begin to plan for commercialization for patients in need.”

“I am excited to join Scholar Rock and be a part of this talented and fast-growing team that is dedicated to moving our programs forward to address unmet medical needs,” said Parlavecchio. “I have been inspired by the Company’s progress and have seen the enormous potential of our clinical programs and scientific platform. I look forward to supporting Scholar Rock’s future by attracting and developing top talent at all stages, from research through commercialization, serving our teams and creating a meaningful and inclusive work experience for all of our employees.”

Ms. Parlavecchio most recently served as Vice President and Chief Human Resources Officer at Holy Name Medical, an acute care facility, for the past year, during which she was a member of the executive team, HR committee, finance committee, and compensation and benefits committees. Prior to, she held various human resource leadership positions during her nearly 20-year tenure at Novartis Pharmaceuticals, including Vice President and Global HR Head, Oncology and Pharma Development, Vice President and Country HR Head, and Vice President, Human Resources Services, North America. Ms. Parlavecchio holds a Master of Arts in Counseling Psychology and a Bachelor of Arts in English, both from Seton Hall University.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Scholar Rock^® is a registered trademark of Scholar Rock, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of new executives to influence Scholar Rock’s progress, Scholar Rock’s ability to develop its pipeline, and Scholar Rock’s growth expectations. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

Contacts

Scholar Rock Contacts:
Investor Contact:
Catherine Hu

[email protected]

Media Contact:
Ariane Lovell

Finn Partners

[email protected]
917-565-2204